Abstract：
COVID-19 has had a major effect on health care activities, especially surgery. At first, comparisons were proposed using 2019 activities as the highest standard. However, while such an approach might have been suitable during the first months of the pandemic, this might no longer be the case for a longer period.
To examine approaches that may better assess the use of cancer surgeries.
In a cross-sectional design, the nationwide French hospital facility data (Medicalised Information System Program) were used to assess cancer surgery for 6 cancer site categories in adults from January 1, 2010, to December 31, 2021.
Estimated cancer surgery activity during the COVID-19 pandemic.
Three models were proposed to assess the expected number of surgical procedures between 2020 and 2021 and make a comparison with those observed in earlier years.
In France, cancer removal surgeries account for approximately 7000 hospitalizations per year for liver cancer; 4000 for pancreatic cancer; 7700 for ovarian cancer; 1300 for esophagus cancer; 23 000 for ear, nose, and throat (ENT) cancer; 78 000 for breast cancer; and 16 600 for thoracic cancers. For most cancer sites, the number of surgical procedures increased from 2010 to 2019: liver, 14%; pancreas, 38%; ovary, 14%; esophagus, 18%; breast, 8%; and thoracic, 29%. Assuming stability, these values underestimate the gap in activity observed in 2020-2021. For other procedures, a decrease was observed: stomach, -10%, and ENT, -6%. Assuming stability, these values overestimate the gap in activity observed in 2020-2021. At the end of 2021, according to the model, the gap in activity observed in 2020-2021 was estimated at between -1.4% and 1.7% for breast, -6.6% and -7.3% for thoracic, -3.1% and -2.5% for ovarian, -4.2% and -1.7% for pancreas, -6.7% and 5.9% for stomach, and -13.0% and -13.9% for esophageal cancers. For ENT, liver, and urologic cancers, because the trend was different before and after 2015, it was necessary to opt for modeling using only the most recent period. The cumulative gap in activity observed in 2020-2021 was estimated at -1.0% for ENT cancers, -5.3% for liver cancers, and -2.9% for urologic cancers.
The findings of this study suggest that short- and medium-term trends must be considered to estimate COVID-19 cancer surgery activities. Breast cancer is the site for which the activity showed the smallest decrease during the pandemic, with almost full recovery in 2021.
To examine approaches that may better assess the use of cancer surgeries.
In a cross-sectional design, the nationwide French hospital facility data (Medicalised Information System Program) were used to assess cancer surgery for 6 cancer site categories in adults from January 1, 2010, to December 31, 2021.
Estimated cancer surgery activity during the COVID-19 pandemic.
Three models were proposed to assess the expected number of surgical procedures between 2020 and 2021 and make a comparison with those observed in earlier years.
In France, cancer removal surgeries account for approximately 7000 hospitalizations per year for liver cancer; 4000 for pancreatic cancer; 7700 for ovarian cancer; 1300 for esophagus cancer; 23 000 for ear, nose, and throat (ENT) cancer; 78 000 for breast cancer; and 16 600 for thoracic cancers. For most cancer sites, the number of surgical procedures increased from 2010 to 2019: liver, 14%; pancreas, 38%; ovary, 14%; esophagus, 18%; breast, 8%; and thoracic, 29%. Assuming stability, these values underestimate the gap in activity observed in 2020-2021. For other procedures, a decrease was observed: stomach, -10%, and ENT, -6%. Assuming stability, these values overestimate the gap in activity observed in 2020-2021. At the end of 2021, according to the model, the gap in activity observed in 2020-2021 was estimated at between -1.4% and 1.7% for breast, -6.6% and -7.3% for thoracic, -3.1% and -2.5% for ovarian, -4.2% and -1.7% for pancreas, -6.7% and 5.9% for stomach, and -13.0% and -13.9% for esophageal cancers. For ENT, liver, and urologic cancers, because the trend was different before and after 2015, it was necessary to opt for modeling using only the most recent period. The cumulative gap in activity observed in 2020-2021 was estimated at -1.0% for ENT cancers, -5.3% for liver cancers, and -2.9% for urologic cancers.
The findings of this study suggest that short- and medium-term trends must be considered to estimate COVID-19 cancer surgery activities. Breast cancer is the site for which the activity showed the smallest decrease during the pandemic, with almost full recovery in 2021.
摘要：
未经批准：COVID-19对医疗保健活动产生了重大影响，尤其是手术。起初,以2019年活动为最高标准，提出了比较建议。然而,虽然这种方法在大流行的头几个月可能是合适的，在更长的时间内，情况可能不再如此。
UNASSIGNED：研究可以更好地评估癌症手术使用的方法。
UNASSIGNED：在横截面设计中，从2010年1月1日至2021年12月31日,法国全国医院设施数据(医疗信息系统计划)用于评估成人6种癌症部位类别的癌症手术.
未经批准：估计COVID-19大流行期间的癌症手术活动。
UNASSIGNED：提出了三种模型来评估2020年至2021年之间的预期外科手术次数，并与前几年观察到的进行比较。
未经批准：在法国，癌症切除手术每年约有7000例肝癌住院；4000例胰腺癌；7700例卵巢癌；1300例食管癌；23000例耳部，鼻子,喉癌（ENT）；乳腺癌78000；胸癌16600。对于大多数癌症部位，从2010年到2019年，外科手术的数量增加了：肝脏，14%；胰腺，38%；卵巢，14%；食管，18%;乳房,8%；和胸部，29%。假设稳定，这些值低估了2020-2021年观察到的活动差距。对于其他程序，观察到减少：胃，-10%,和ENT,-6%。假设稳定，这些值高估了2020-2021年观察到的活动差距。根据该模型，到2021年底，2020-2021年观察到的乳腺活动差距估计在-1.4%至1.7%之间，-6.6%和-7.3%的胸廓，-3.1%和-2.5%的卵巢，胰腺为-4.2%和-1.7%，-6.7%和5.9%的胃，食管癌为-13.0%和-13.9%。对于ENT,肝脏,和泌尿系癌症，由于2015年前后趋势不同，因此有必要选择仅使用最近的时间段进行建模。ENT癌症在2020-2021年观察到的活动累积差距估计为-1.0%，肝癌-5.3%，泌尿系癌症为-2.9%。
UNASSIGNED：这项研究的结果表明，必须考虑短期和中期趋势来估计COVID-19癌症手术活动。乳腺癌是大流行期间活动下降最小的部位，2021年几乎完全复苏。
UNASSIGNED：研究可以更好地评估癌症手术使用的方法。
UNASSIGNED：在横截面设计中，从2010年1月1日至2021年12月31日,法国全国医院设施数据(医疗信息系统计划)用于评估成人6种癌症部位类别的癌症手术.
未经批准：估计COVID-19大流行期间的癌症手术活动。
UNASSIGNED：提出了三种模型来评估2020年至2021年之间的预期外科手术次数，并与前几年观察到的进行比较。
未经批准：在法国，癌症切除手术每年约有7000例肝癌住院；4000例胰腺癌；7700例卵巢癌；1300例食管癌；23000例耳部，鼻子,喉癌（ENT）；乳腺癌78000；胸癌16600。对于大多数癌症部位，从2010年到2019年，外科手术的数量增加了：肝脏，14%；胰腺，38%；卵巢，14%；食管，18%;乳房,8%；和胸部，29%。假设稳定，这些值低估了2020-2021年观察到的活动差距。对于其他程序，观察到减少：胃，-10%,和ENT,-6%。假设稳定，这些值高估了2020-2021年观察到的活动差距。根据该模型，到2021年底，2020-2021年观察到的乳腺活动差距估计在-1.4%至1.7%之间，-6.6%和-7.3%的胸廓，-3.1%和-2.5%的卵巢，胰腺为-4.2%和-1.7%，-6.7%和5.9%的胃，食管癌为-13.0%和-13.9%。对于ENT,肝脏,和泌尿系癌症，由于2015年前后趋势不同，因此有必要选择仅使用最近的时间段进行建模。ENT癌症在2020-2021年观察到的活动累积差距估计为-1.0%，肝癌-5.3%，泌尿系癌症为-2.9%。
UNASSIGNED：这项研究的结果表明，必须考虑短期和中期趋势来估计COVID-19癌症手术活动。乳腺癌是大流行期间活动下降最小的部位，2021年几乎完全复苏。
